Protocol Ledger

NCT07133308 · Phase III · RECRUITING

Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia Areata

Interventional Phase III clinical trial protocol NCT07133308 sponsored by Sun Pharmaceutical Industries in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-08-05 Enrollment: 355 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07133308
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)355 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07133308
Protocol FieldVerified Registry Value
NCT IdentifierNCT07133308
Consolidated Lead SponsorSun Pharmaceutical Industries
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment355 participants (ESTIMATED)
Registered Start Date2025-08-05
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07133308
Hospital Research SiteLocationSite Profile
Center for Dermatology Clinical Research, Inc.Fremont, CAOpen Hospital Dossier ->
Dermatology Research AssociatesLos Angeles, CAOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI